title: Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience.
abstract: The recent proposal for histological subtyping of pulmonary adenocarcinoma by predominant pattern and introduction of the terms adenocarcinoma in situ and minimally invasive adenocarcinoma to replace the term bronchioloalveolar carcinoma by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society has led us to conduct a study of 104 patients with early-stage primary pulmonary adenocarcinoma (T1N0M0), with a view to histological subtype as defined by the new proposal and clinical outcome. None of the clinical parameters of our patient population (type of surgery, age, gender, tumor size, and comorbidities) showed any statistically significant correlation with outcome, except for associated malignancies, which not surprisingly appeared to have a negative impact on survival. In addition, statistical analyses of the histological characteristics to include tumor differentiation and the percentage of a lepidic or bronchioloalveolar component did not show any statistically significant values in terms of survival. Our results failed to show any statistically significant difference of survival between those T1N0M0 adenocarcinomas with a lepidic component and those without, thus questioning the use of terms such as in situ or minimally invasive adenocarcinoma. On the basis of our results, we consider that the outcome for patients with T1N0M0 disease is still best determined by appropriate staging rather than by changes in the pathology nomenclature of adenocarcinoma.
authors.affiliation: Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA. aweissferdt@doctors.org.uk
authors.forename: Annikka
authors.initials: A
authors.lastname: Weissferdt
authors.forename: Neda
authors.initials: N
authors.lastname: Kalhor
authors.forename: Edith M
authors.initials: EM
authors.lastname: Marom
authors.forename: Marcelo F
authors.initials: MF
authors.lastname: Benveniste
authors.forename: Myrna C
authors.initials: MC
authors.lastname: Godoy
authors.forename: Arlene M
authors.initials: AM
authors.lastname: Correa
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Swisher
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Moran
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D016896:Treatment Outcome